BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210302
DTEND;VALUE=DATE:20210306
DTSTAMP:20210225T232420Z
CREATED:20210225T232420Z
LAST-MODIFIED:20210225T232420Z
UID:48654-1614643200-1614988799@globalbiodefense.com
SUMMARY:Effectiveness of Non-Vaccine Influenza Control Measures
DESCRIPTION:The National Academies will host a first committee meeting on Effectiveness of Non-Vaccine Influenza Control Measures on March 2-5\, 2021 in virtual format. \nThe event supports the Health and Medicine Division’s Public Health Interventions and Countermeasures for Advancing Pandemic and Seasonal Influenza Preparedness and Response project. \nThe global response to COVID-19 has pushed the boundaries of preparedness for a respiratory virus. At the request of the Office of Global Affairs within the U.S. Department of Health and Human Services\, the National Academies has convened a committee to analyze how the response to COVID-19 and related events could inform efforts to strengthen future preparedness for and response to seasonal and pandemic influenza. This committee will review non-vaccine public health interventions and countermeasures that can be vital to mitigating the spread and impact of a respiratory virus both before and after vaccines are available. \n\n\nThese virtual events (March 2\, 4\, and 5) will feature speakers with expertise on therapeutics\, non-vaccine public health interventions\, as well as surveillance for influenza and COVID-19. \nPlease visit the Effectiveness of Non-Vaccine Influenza Control Measures webpage for more information. \n 
URL:https://globalbiodefense.com/event/effectiveness-of-non-vaccine-influenza-control-measures/
CATEGORIES:Webinar-Webcast,Workshop
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210302T160000
DTEND;TZID=America/New_York:20210302T180000
DTSTAMP:20210225T162756Z
CREATED:20210225T154652Z
LAST-MODIFIED:20210225T162756Z
UID:48622-1614700800-1614708000@globalbiodefense.com
SUMMARY:RNA Viruses: How They Do What They Do
DESCRIPTION:A virtual presentation on “RNA Viruses: How They Do What They Do” will be held on March 2\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speakers \nDr. Nihal Altan-Bonnet received her B.A. in biology and chemistry from Hunter College\, New York in 1992 and her Ph.D. in cell biology from The Rockefeller University in 1998. She then conducted postdoctoral research with Dr. Jennifer Lippincott-Schwartz at the National Institute of Child Health and Development at the NIH from 1999 to 2005 before receiving a faculty position in the department of biological sciences at Rutgers University. In 2013\, Dr. Altan-Bonnet returned to the NIH as an Earl Stadtman Investigator\, becoming head of the Laboratory of Host-Pathogen Dynamics at the NHLBI and was promoted to tenured Senior investigator in 2017. Dr. Altan-Bonnet has been recognized several times for her outstanding research\, receiving the Presidential Early Career Award in Science and Engineering (PECASE) in 2012\, being named the John J. Holland lecturer at the American Society of Virology in 2017\, and receiving the Norman Salzman Mentor Award in Virology in 2018. Dr. Altan-Bonnet was also named a Kavli Fellow and Scialog Fellow from 2013-2016. She is an Associate editor at the Molecular Biology of the Cell and is a member of the American Societies for Virology\, Microbiology\, and Cell Biology. \nKarla Kirkegaard\, Ph.D.\, is the Violetta L. Horton Research Professor of Genetics and former Chair of the Department of Microbiology and Immunology in the Stanford University School of Medicine. She received her Ph.D. in Biochemistry and Molecular Biology with James C. Wang at Harvard University\, and performed her postdoctoral work in the laboratory of David Baltimore at the Whitehead Institute. As an Assistant and Associate Professor at the University of Colorado in Boulder\, she received numerous awards\, including a fellowship from the David and Lucile Packard Foundation\, an American Cancer Society Young Investigator Award\, a Searle Scholar Award\, and sponsorship by the Howard Hughes Medical Institute. Dr. Kirkegaard combined her interests in biochemistry\, cell biology\, and genetics in the study of RNA virology\, using poliovirus and other positive-strand RNA viruses to understand the cell biology of viral infections and the genetics of viral variability. Since her move to Stanford University School of Medicine in 1996\, her interests have focused increasingly on the impact of basic science discoveries on the transmission of viruses in infected hosts. Kirkegaard’s honors include an Ellison Foundation Senior Scholar Award in Global Infectious Disease and\, in 2006\, the NIH Director’s Pioneer Award\, for her approach to guide the selection of antiviral targets with the goal of suppressing the drug-resistant RNA genomes that will inevitably be formed due to the high error rates of RNA replication. She has been recently elected as a Member of the National Academies of Arts and Sciences and a Fellow of the American Association for the Advancement of Science. Her work continues to focus on the mechanisms of diversity and propagation of viruses and suppression of this diversity and spread. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/rna-viruses-how-they-do-what-they-do/
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
LOCATION:https://videocast.nih.gov/watch=41288
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210308
DTEND;VALUE=DATE:20210311
DTSTAMP:20210225T233052Z
CREATED:20210125T232650Z
LAST-MODIFIED:20210225T233052Z
UID:48656-1615161600-1615420799@globalbiodefense.com
SUMMARY:Quantum-Enabled Sensing and Imaging for Biology
DESCRIPTION:Quantum Science Concepts in Enhancing Sensing and Imaging Technologies: Applications for Biology—A Workshop will be held March 8-10\, 2021 via virtual format. \nThe National Academies of Sciences\, Engineering\, and Medicine is organizing this workshop on the research and development needs to advance biological applications of quantum-enabled sensing and imaging technologies. \nThis event is open to the public and is meant for a broad scientific audience\, including anyone with interest in biology\, chemistry\, physics\, or engineering. The workshop is intended to bring together experts working on state-of-the-art quantum-enabled technologies with scientists who are interested in applying these technologies to biological systems. Through talks\, panels\, and discussions\, the workshop will facilitate a better understanding of the current and future biological applications of quantum-enabled technologies on fields such as microbiology\, molecular biology\, cell biology\, plant science\, mycology\, and many others. Please register below\, and we will be in touch as the agenda continues to develop. \nThe presentations and discussions may explore the following: \n\nThe history of and terminology for quantum sensing and imaging technologies\, as well as any established biological applications.\nDescriptions of current biological applications of quantum sensing and imaging as well as other potential areas of biology where these technologies might be applied.\nUnderstanding what advantages are imparted by quantum-enabled sensing and imaging technologies over their classical counterparts. For example\, will these technologies provide a better signal-to-noise ratio\, better depth of interaction (to image deep-seated signals)\, or increase the spatial and temporal resolution of imaging cellular and molecular functionalities?\nDetermining what disadvantages\, strategies\, feasibility\, and technical needs must be addressed for applying the principles of quantum sensing and imaging to advance the fields of interest in biology. How might the demonstrated uses of quantum approaches in other fields be adaptable to plant science\, microbiology\, and mycology\, especially for work in intracellular molecular phenomena and intercellular interactions? What impediments must be overcome for these applications to succeed\, and what investments could help drive the convergence of these disparate fields forward?\nExploring how the applications of these technologies could have broader impacts in areas such as the development of renewable energy sources\, understanding the effects of earth systems changes on biota\, and the advancement of biotechnology.\nIdentifying the education\, training\, and workforce needs for advancing quantum sensing and imaging technologies in biology.\n\nThis workshop is made possible through the generous support of the U.S. Department of Energy – Biological and Environmental Research Program. \nRegistration is available at: https://quantum-and-bio.heysummit.com/
URL:https://globalbiodefense.com/event/quantum-enabled-sensing-and-imaging-for-biology/
CATEGORIES:Workshop
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210309
DTEND;VALUE=DATE:20210312
DTSTAMP:20210225T235017Z
CREATED:20210225T235017Z
LAST-MODIFIED:20210225T235017Z
UID:48660-1615248000-1615507199@globalbiodefense.com
SUMMARY:The Current Global Governance Landscape for Influenza
DESCRIPTION:The Health and Medicine Division of the National Academies will convene a virtual committee meeting on the Current Global Governance Landscape for Influenza on March 9-11\, 2021. \nThis first meeting of the committee will serve for the committee to begin to analyze the major global frameworks\, regulations\, and partnerships for influenza vaccine preparedness and response. \nOpen sessions will feature discussions with speakers\, including the sponsor and global health leaders\, about considerations that led to the launch of this consensus study and gaps in or barriers to implementation of current global mechanisms for influenza vaccine development\, manufacturing\, and access. The meeting will allow committee members to identify areas of concentration within the study’s statement of task and determine what information gathering will be required for to make recommendations for these areas. \nPlease visit NASEM’s Current Global Governance Landscape for Influenza Vaccines webpage for more information.
URL:https://globalbiodefense.com/event/the-current-global-governance-landscape-for-influenza/
CATEGORIES:Webinar-Webcast,Workshop
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210309T110000
DTEND;TZID=America/New_York:20210310T160000
DTSTAMP:20210226T160748Z
CREATED:20210126T154128Z
LAST-MODIFIED:20210226T160748Z
UID:48669-1615287600-1615392000@globalbiodefense.com
SUMMARY:Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic
DESCRIPTION:The National Academies will host a committee meeting on Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic: Lessons Learned from March 9-10\, 2021. \nRapid (and Precise) COVID-19 Vaccine Development\nBarney Graham\, M.D.\, Ph.D.\, Deputy Director\, Vaccine Research Center\, NIAID\, NIH \nThe COVID-19 Pandemic: The Triumphs and Challenges of Vaccine Development and Use of Animal Models in the Midst of a Pandemic\nIan Moore\, D.V.M.\, Ph.D.\, DACVP\, Investigative Veterinary Pathologist and Section Chief\, Infectious Disease\nPathogenesis Section\, NIAID\, NIH \nBringing Together Stakeholders: Users and Resources\nFranziska Grieder\, D.V.M.\, Ph.D.\, Director\, Office of Research Infrastructure Program\, Division of Program Coordination\, Planning\, and Strategic Initiatives\, NIH \nLessons Learned: NHP Supply\nKurt Derfler\, M.B.A.\, Executive Director of Operations\, Charles River Laboratories \nNonhuman Primate Importation During the SARS-CoV-2 Pandemic\nGale Galland\, D.V.M.\, M.S.\, DACVPM\, Veterinary Medical Officer\, Zoonoses Team\, Quarantine Border Health Services Branch\, Division of Global Migration and Quarantine\, CDC \nOccupational Health in a Pandemic\nMaureen Thompson\, BSN\, RN\, COHN\, RBP(ABSA)\, Safety Officer\, Yerkes National Primate Research Center\nAssociate Director\, Environmental Health and Safety Office\, Emory University \nRisk Assessment and Biosafety Support for SARS-CoV-2 and COVID-19 Research: Challenges in Established ABSL-2 and ABSL-3 Research Programs\nMolly Stitt-Fisher\, PhD\, CPH\, CBSP\, SM(NRCM)\, Rebecca Lingenfelter\, MSPH\, University Biosafety\, Officer/Associate Biosafety Officer and Alternate Responsible\, Official for Select Agents\, Department of Environmental Health and Safety\, University of Pittsburgh \nPublic Messaging and Communications About Animal-Based Research During the COVID-19 Pandemic\nJames O’Reilly\, B.A.\, President\, Massachusetts Society for Medical Research \nVirus Sequence Data During an Outbreak\nEneida Hatcher\, Ph.D.\, Contractor\, National Center for Biotechnology Information\, National Library of Medicine\,\nNIH \nThe Nonhuman Primate Model of SARS-CoV-2 to Test Therapeutic Strategies: Overcoming Challenges and Obstacles Towards Proof of Concept\nKoen Van Rompay\, D.V.M.\, Ph.D.\, Full Research Virologist\, California National Primate Research Center\nUC Davis \nFast Tracking Animal Model Development\, Collaborations\, and Research to Deliver Preclinical Data for Vaccine Antigen Selection\nIsis Kanevsky\, Ph.D.\, Director\, Vaccine Research Unit\, Pfizer \nManagement of a Nonhuman Primate Colony During SARS-CoV-2\nJoyce Cohen\, V.M.D.\, DACLAM\, Associate Director\, Division of Animal Resources\, Yerkes National Primate Research Center\, Emory University \nMaintaining Animal Research Continuity in the Time of COVID-19\nMichael J. Huerkamp\, D.V.M.\, DACLAM\nExecutive Director\, Division of Animal Resources\nEmory University \nResiliency in Animal Research Operations – COVID-19 Lessons Learned: Direct Staffing Impacts\nCDR Temeri Wilder-Kofie\, D.V.M.\, MPH\, DACLAM\, Facility Veterinarian\, Comparative Medicine Branch\, NIAID\, NIH \nResiliency in Animal Research Operations: Laboratory Animal Program Operations and Management Impacts\nJill Ascher\, M.A.\, D.V.M.\, MPH\, DACLAM\, Director\, Division of Veterinary Resources\, Office of Research Services\nNIH \nImpact of the COVID-19 Pandemic on Animal Research\nLori Palley\, D.V.M.\, DACLAM\, Assistant Director of Veterinary Services\, Center for Comparative Medicine\nMassachusetts General Hospital \nFinancial Impact of the COVID-19 Pandemic on Academic Animal Care Programs\nLucy Kennedy\, D.V.M.\, DACLAM\, Assistant Director for Clinical Services and Assistant Attending Veterinarian\, Unit for Laboratory Animal Medicine\, University of Michigan \nEvolving Prioritizations of In Vivo Research in Pharma During the COVID-19 Pandemic\nSean Maguire\, V.M.D.\, M.S.\, MRCVS\, DACLAM\, Comparative & Translational Sciences Director & Associate Fellow\, GlaxoSmithKline \nIntegrating the Institution’s COVID-19 Response Plan into the Research Animal Program\nStephen Denny\, D.V.M.\, M.S.\, DACLAM\, DACVPM\, Director\, Office of Animal Care and Use Office of Intramural Research\, NIH \nPanel Discussion – Resiliency in Animal Research Operations\nOpen panel discussion with audience participation \nPanelists: \n\nAcademia: Mike Huerkamp\, Lucy Kennedy\nGovernment: Jill Ascher\, Temeri Wilder-Kofie\, Stephen Denny\nIndustry – Pharma: Sean Maguire\nPrimate Research Center: Joyce Cohen\nAnimal Research Advocate: James O’Reilly\n\n\nMeeting Materials\n\n\n\nRapid Response Workshop Agenda\nSpeaker Abstracts\nSpeaker Biographies\n\n\nPlease visit the Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic: Lessons Learned page for more information.
URL:https://globalbiodefense.com/event/rapid-response-by-laboratory-animal-research-institutions-during-the-covid-19-pandemic/
CATEGORIES:Webinar-Webcast,Workshop
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/02/rapid-response-animal-research-lab-covid-countermeasures-nasem.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210309T160000
DTEND;TZID=America/New_York:20210309T180000
DTSTAMP:20210225T163128Z
CREATED:20210225T155238Z
LAST-MODIFIED:20210225T163128Z
UID:48625-1615305600-1615312800@globalbiodefense.com
SUMMARY:Ethics in Vaccine Development\, Testing and Use Making a COVID-19 Vaccine
DESCRIPTION:A virtual presentation on “Ethics in Vaccine Development\, Testing and Use Making a COVID-19 Vaccine” will be held on March 9\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speakers \nKizzmekia Corbett\, PhD is a research fellow and the scientific lead for the Coronavirus Vaccines & Immunopathogenesis Team at the National Institutes of Health (NIH)\, National Institute of Allergy and Infectious Diseases\, Vaccine Research Center (VRC). She received a B.S. in Biological Sciences\, with a secondary major in Sociology\, in 2008 from the University of Maryland – Baltimore County\, where she was a Meyerhoff Scholar and an NIH undergraduate scholar. She then enrolled at University of North Carolina at Chapel Hill\, where she obtained her Ph.D. in Microbiology and Immunology in 2014. A viral immunologist by training\, Dr. Corbett uses her expertise to propel novel vaccine development for pandemic preparedness. Appointed to the VRC in 2014\, her work focuses on developing novel coronavirus vaccines\, including mRNA-1273\, a leading candidate vaccine against the virus that causes COVID-19. In response to the ongoing global COVID-19 pandemic\, the vaccine concept incorporated in mRNA-1273 was designed by Dr. Corbett’s team from viral sequence data and rapidly deployed to industry partner\, Moderna\, Inc.\, for U.S. Food and Drug Administration (FDA)-approved Phase 1 clinical trial\, which unprecedently began only 66 days from the viral sequence release. Following promising results in animal models and humans\, mRNA-1273 is currently in Phase 3 clinical trial. Alongside mRNA-1273\, Dr. Corbett’s team boasts a portfolio that also includes universal coronavirus vaccine concepts and novel therapeutic antibodies. Additionally\, Dr. Corbett spent several years working on a universal influenza vaccine\, which is slated for Phase 1 clinical trial. In all\, she has 15 years of expertise studying dengue virus\, respiratory syncytial virus\, influenza virus and coronaviruses. Along with her research activities\, Dr. Corbett is an active member of the NIH Fellows Committee and avid advocator of STEM education and vaccine awareness in the community. Combining her research goals with her knack for mentoring\, Dr. Corbett aims to become an independent principal investigator. \nChristine Grady\, PhD is a nurse-bioethicist and a senior investigator who currently serves as the Chief of the Department of Bioethics. Dr. Grady has authored more than 175 papers in the biomedical and bioethics literature and authored or edited several books\, including The Oxford Textbook of Clinical Research Ethics. She served from 2010-2017 as a Commissioner on the President’s Commission for the Study of Bioethical Issues. Her work is known internationally\, and she has lectured widely on ethical issues in clinical research and clinical care\, HIV disease\, and nursing. She is an elected fellow of the Hastings Center and of the American Academy of Nursing\, a senior research fellow at the Kennedy Institute of Ethics and an elected member of the National Academy of Medicine. She holds a BS in nursing and biology from Georgetown University\, a MSN. in community health nursing from Boston College\, and a PhD in philosophy from Georgetown University. She has participated in numerous intergovernmental task forces and is the recipient of several awards\, including the NIH CEO Award in 2017\, and the NIH Director’s Award in 2015 and 2017. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/ethics-in-vaccine-development-testing-and-use-making-a-covid-19-vaccine/
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
LOCATION:https://videocast.nih.gov/watch=41289
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210316
DTEND;VALUE=DATE:20210320
DTSTAMP:20210226T142745Z
CREATED:20210226T142627Z
LAST-MODIFIED:20210226T142745Z
UID:48662-1615852800-1616198399@globalbiodefense.com
SUMMARY:Examining the Long-term Health and Economic Effects of Antimicrobial Resistance in the United States
DESCRIPTION:The National Academies will convene a meeting Examining the Long-term Health and Economic Effects of Antimicrobial Resistance in the United States on March 16-19\, 2021 via virtual format. \nDuring these meetings\, expert speakers will discuss GARP’s work developing treatments for drug-resistant infections and CMS reimbursement for new antibiotics. Speakers will also present on the challenges of using genomic data for surveillance and the role of next-generation sequencing and predictive modeling. \nThe following portions of the meeting are open to the public: \n\nMarch 16\, 2021\, 11:00am – 12:05pm ET\nMarch 19\, 2021\, 11:00am – 11:45pm ET\n\nThe agenda for the open session include a discussion of: \n\nGARDP and Antimicrobial Development\, Jennifer Schneider\, Senior Advisor External Affairs\, Global Antibiotic R&D\, Partnership\nInpatient Reimbursement and the Antimicrobial Market\, Anand Shah\, former Deputy Commissioner for Medical and Scientific Affairs\, FDA\nDirect\, Predictive Application of Sequencing and Informatics\, Gautam Dantas\, Professor\, Washington University School of Medicine\n\nDuring the closed sessions across both days\, the committee members will discuss draft recommendations and conclusions in the following areas: \n\nPush and Pull Incentives\nInternational Action\nHealth and Economic Burden\nSurveillance
URL:https://globalbiodefense.com/event/examining-the-long-term-health-and-economic-effects-of-antimicrobial-resistance-in-the-united-states/
CATEGORIES:Webinar-Webcast,Workshop
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210316T150000
DTEND;TZID=America/New_York:20210316T170000
DTSTAMP:20210225T160929Z
CREATED:20210225T160929Z
LAST-MODIFIED:20210225T160929Z
UID:48629-1615906800-1615914000@globalbiodefense.com
SUMMARY:Consequences of Retroviral DNA Integration to AIDS and Evolution
DESCRIPTION:An NIH virtual presentation entitled “These Viruses are Forever: Consequences of Retroviral DNA Integration to AIDS and Evolution” will be held on March 16\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speaker \nJohn Coffin is an American Cancer Society Professor of Molecular Biology\, Tufts Graduate School of Biomedical Sciences \nEducation:\nBA\, Biology\, Wesleyan University\nPhD\, Molecular Biology\, University of Wisconsin\, Madison\nPostdoctoral Training\, Institut für Molekularbiologie\, University of Zürich \nOur research interests revolve around obtaining a better understanding of the interaction of retroviruses with their host cells and organisms. We use simple retroviruses (avian and murine viruses) as well as HIV to elucidate the nature of the retrovirus-receptor interaction; control of viral gene expression; mechanism of retroviral genetic variation; and evolution of the host-virus relationship\, as revealed by the fossil record provided by endogenous proviruses found in the normal DNA of all vertebrates and many other species. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/consequences-of-retroviral-dna-integration-to-aids-and-evolution/
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210324T110000
DTEND;TZID=America/New_York:20210324T150000
DTSTAMP:20201127T193612Z
CREATED:20201127T193433Z
LAST-MODIFIED:20201127T193612Z
UID:48061-1616583600-1616598000@globalbiodefense.com
SUMMARY:Envisioning a Transformed Clinical Trials Enterprise for 2030 - Session 3
DESCRIPTION:The National Academies’ Forum on Drug Discovery\, Development\, and Translation will host a virtual public workshop on Mar 24\, 2021 as part of a web series forum of events to discuss critical policy for advancement of biopharmaceutical innovation nationally and globally. \nThis virtual public workshop will provide a venue for stakeholders to consider a transformed clinical trial enterprise for 2030. Workshop participants will consider lessons learned from progress and setbacks over the past 10 years\, since the previous workshop\, Envisioning a Transformed Clinical Trials Enterprise in the United States\, and\, looking forward\, discuss goals and key priorities for advancing a clinical trials enterprise that is more efficient\, effective\, person-centered\, inclusive\, and integrated into the health delivery system of 2030. \nThe event will consider approaches to build resilience\, sustainability\, and transparency. The discussion will include the convergence and integration of clinical research and clinical practice; data sharing and management; and efficient\, engaging scientific communication. \nBackground\nClinical trials research has changed dramatically over the last decade. The biological\, physical\, and digital spheres are merging; clinical research and health care are at a critical juncture; new approaches enable the collection of data in real-world settings; and new modalities\, such as digital health technologies and artificial intelligence applications\, are changing possibilities for the conduct of clinical research. \nA planning committee of the National Academies of Sciences\, Engineering\, and Medicine will plan and conduct a virtual public workshop designed to consider a transformed clinical trial enterprise for 2030. Key priority challenges and opportunities framing the 2030 agenda are: \n\nDiversity and inclusion of clinical trial participants\nConvergence of clinical research and clinical practice\nClinical trial data sharing\nIncorporation of new technologies into drug research and development\nWorkforce and career development\nPublic engagement and partnership\nRegulatory Environment\nCultural and Financial Incentives\nPractical short- and long-term goals for improving the efficiency\, effectiveness\, person-centeredness\, inclusivity\, and integration with healthcare of the clinical trials enterprise.\n\nFor additional information on the workshop series\, please visit the project page.
URL:https://globalbiodefense.com/event/envisioning-a-transformed-clinical-trials-enterprise-for-2030-session-3/
CATEGORIES:Webinar-Webcast,Workshop
LOCATION:https://bit.ly/nasem-clinicaltrialenterprise
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210330T160000
DTEND;TZID=America/New_York:20210330T180000
DTSTAMP:20210225T161411Z
CREATED:20210225T161411Z
LAST-MODIFIED:20210225T161411Z
UID:48631-1617120000-1617127200@globalbiodefense.com
SUMMARY:How COVID-19 Pandemic Changes Medical Research\, Teaching and Patient Care
DESCRIPTION:A virtual presentation on “How COVID-19 Pandemic Changes Medical Research\, Teaching and Patient Care” will be held on March 20\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speaker \nEzekiel J. Emanuel is the Vice Provost for Global Initiatives\, the Diane v.S. Levy and Robert M. Levy University Professor\, and Co-Director of the Healthcare Transformation Institute at the University of Pennsylvania. From January 2009 to January 2011\, Dr. Emanuel served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. Prior to that he was the founding chair of the Department of Bioethics at the National Institutes of Health from 1997 to August of 2011. Dr. Emanuel received his M.D. from Harvard Medical School and his Ph.D. in political philosophy from Harvard University. After completing his internship and residency in internal medicine at Boston’s Beth Israel Hospital and his oncology fellowship at the Dana-Farber Cancer Institute\, he joined the faculty at the Dana-Farber Cancer Institute. He has since been a visiting professor at the University of Pittsburgh School of Medicine\, UCLA\, the Brin Professor at Johns Hopkins Medical School\, and the Kovitz Professor at Stanford Medical School and visiting professor at New York University Law School. Dr. Emanuel served on President Clinton’s Health Care Task Force\, the National Bioethics Advisory Commission (NBAC)\, and on the bioethics panel of the Pan-American Healthcare Organization. He has published over 300 articles mainly on health care reform\, research ethics\, and end of life care. He has also authored or edited 15 books. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/how-covid-19-pandemic-changes-medical-research-teaching-and-patient-care/
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
LOCATION:https://videocast.nih.gov/watch=41575
END:VEVENT
END:VCALENDAR